概括
升高的氨基酸细胞驱动2型炎症性疾病. 梅波利祖马布 (Mepolizumab) 是一种抗联素-5疗法,有效地降低了埃索因菲尔细胞的数量,为慢性埃索因菲尔病症提供了新的治疗选择.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 过敏和临床免疫学
背景情况:
- 乙氨基在2型炎症性慢性疾病中起着关键作用.
- 了解埃索诺菲尔驱动疾病的进步导致了向治疗.
- 生物制剂的发展显著改善了对这些疾病的管理.
研究的目的:
- 要总结mepolizumab的药理概况.
- 概述了梅波利祖马布在慢性埃索诺菲尔性疾病中的当前适用情况.
- 提供mepolizumab作用机制的清晰概述.
主要方法:
- 对梅波利祖马布的药理学数据的审查.
- 对美波利祖马布在eosinophilic疾病的临床试验结果的分析.
- 综合当前的监管批准和指示.
主要成果:
- 梅波利祖马布是一种人性化的单克隆抗体,向插白素-5 (IL-5).
- 梅波利祖马布对IL-5的阻断会导致埃索诺菲尔水平的降低.
- 临床研究表明,这种药物在各种慢性乙酸性疾病中具有有效性.
结论:
- 梅波利祖马布提供了一种有针对性的方法来管理与高氨基相关的疾病.
- 药物的作用机制为其在2型炎症条件下使用提供了合理的基础.
- 目前的适应症突出显示了mepolizumab在治疗特定的慢性乙酸性疾病中的价值.
更多相关视频
09:58A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
Published on: April 13, 2010
22.5K
05:31Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
Published on: August 7, 2017
10.4K
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
313
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
313
Antiasthma Drugs: Methylxanthines
246
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
246
Antiasthma Drugs: Muscarinic Receptor Antagonists
320
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
320
Antiasthma Drugs: Leukotriene Modifiers
324
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
324
Drugs Used in Lower Respiratory Disorders: Overview
462
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
462
Adrenergic Agonists: Mixed-Action Agents
756
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
756
